Click here to receive MS news via e-mail
EXPAND study shows 21% reduction in 3-month confirmed disability progression
September 17, 2016
LONDON — A novel sphingosine-1-phosphate (S1P) receptor modulator may stall disability progression in patients with secondary progressive MS, researchers reported here.
In the EXPAND study, SPMS patients on siponimod had a 21% reduced risk of 3-month confirmed disability progression compared with those on placebo (HR 0.79, 95% CI 0.65 to 0.95, P=0.013), Ludwig Kappos, MD, of University Hospital Basel in Switzerland, reported during a late-breaking session at the ECTRIMS meeting here.
The drug also hit a number of key secondary endpoints, with the exception of the timed 25-foot walk test (T25FW), which trended in the right direction but wasn’t significant, Kappos reported.
As seen in earlier studies, it also didn’t carry the cardiac initial dosing effects often occurring with fingolimod (Gilenya), he said.
MS Views and News
Providing educational information, resources and services for those affected by MS
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews